NCT07213830
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07213830
Title A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Ipsen
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | FRA | ESP | CAN

Facility Status City State Zip Country Details
Dana-Farber Cancer Institute NOT_YET_RECRUITING Boston Massachusetts 02215 United States Details
START MidWest PI Sharma RECRUITING Grand Rapids Michigan 49546 United States Details
Sarah Cannon Research Institute PI McKean Nasville, TN, USA RECRUITING Nashville Tennessee 37205 United States Details
MD Anderson PI Champiat NOT_YET_RECRUITING Houston Texas 77030 United States Details
Start San Antonio PI Rasco RECRUITING San Antonio Texas 78229 United States Details
NEXT PI Spira NOT_YET_RECRUITING Fairfax Virginia 22031 United States Details
Princess Margaret Cancer Center PI Spreafico RECRUITING Toronto Canada Details
Gustave Roussy Cancer Campus Grand Paris- (Institut de Cancerologie Gustave-Roussy) - PI Ronan NOT_YET_RECRUITING Villejuif France Details
Hospital Universitario Vall d'Hebron PI Garralda Cabanas NOT_YET_RECRUITING Barcelona Spain Details
NEXT Quiron-Barcelona - PI Saavedra Santa Gadea RECRUITING Barcelona Spain Details
START Madrid - CIOCC. Grupo Hospital de Madrid (HM) - Centro Integral Oncologico Clara Campal (CIOCC) - Calvo Aller RECRUITING Madrid Spain Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field